Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
Abbi
Kamal K S
KK
Rizvi
Syed M
SM
Sivik
Jeffrey
J
Thyagarajan
Subramanian
S
Loughran
Thomas
T
Drabick
Joseph J
JJ
D000368:Aged; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D015551:Autoimmunity / Q000187:drug effects; D000074301:CD52 Antigen; D003131:Combined Modality Therapy; D003171:Complement Pathway, Classical; D003713:Dendritic Cells / Q000187:drug effects; D006023:Glycoproteins / Q000037:antagonists & inhibitors / Q000276:immunology; D020275:Guillain-Barre Syndrome / Q000139:chemically induced* / Q000628:therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D015461:Leukemia, Prolymphocytic, T-Cell / Q000188:drug therapy*; D008297:Male; D010956:Plasmapheresis; D012121:Respiration, Artificial; D016176:T-Lymphocyte Subsets / Q000187:drug effects
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; D006023:Glycoproteins; D016756:Immunoglobulins, Intravenous; D000074323:Alemtuzumab